Ontology highlight
ABSTRACT: Background
We studied the efficacy and safety of selenium supplementation in patients who had peripartum cardiomyopathy (PPCM) and selenium deficiency.Methods
We randomly assigned 100 PPCM patients with left ventricular ejection fraction (LVEF)?ResultsOver a median of 19 months, the primary outcome occurred in 36 of 46 patients (78.3%) in the selenium group and in 43 of 54 patients (79.6%) in the control group (hazard ratio [HR] 0.69; 95% confidence interval [CI] 0.43-1.09; p?=?0.113). Persistence of HF symptoms occurred in 18 patients (39.1%) in the selenium group and in 37 patients (68.5%) in the control group (HR 0.53; 95% CI 0.30-0.93; p?=?0.006). LVEF?ConclusionsIn this study, selenium supplementation did not reduce the risk of the primary outcome, but it significantly reduced HF symptoms, and there was a trend towards a reduction of all-cause mortality.Clinical trial registration
ClinicalTrials.gov Identifier: NCT03081949.
SUBMITTER: Karaye KM
PROVIDER: S-EPMC7579991 | biostudies-literature | 2020 Oct
REPOSITORIES: biostudies-literature
Karaye Kamilu M KM Sa'idu Hadiza H Balarabe Suleiman A SA Ishaq Naser A NA Sanni Bushra B Abubakar Haruna H Mohammed Baba Lawan BL Abdulsalam Tijjani T Tukur Jamilu J Mohammed Idris Y IY
BMC cardiovascular disorders 20201021 1
<h4>Background</h4>We studied the efficacy and safety of selenium supplementation in patients who had peripartum cardiomyopathy (PPCM) and selenium deficiency.<h4>Methods</h4>We randomly assigned 100 PPCM patients with left ventricular ejection fraction (LVEF) < 45% and selenium deficiency (< 70 μg/L) to receive either oral Selenium (L-selenomethionine) 200 μg/day for 3 months or nothing, in addition to recommended therapy, in an open-label randomised trial. The primary outcome was a composite o ...[more]